Shares of Argenx SE (NASDAQ: ARGX) surged over 9% in pre-market trading on Wednesday after the biopharmaceutical company reported stellar third quarter 2024 financial results that trounced analysts' estimates.
For the quarter ended September 30, Argenx posted earnings per share of $1.39, obliterating the consensus estimate of just $0.02. The company's revenue of $588.9 million also surpassed expectations, coming in 9.35% higher than the $538.5 million analysts had forecast.
The blockbuster Q3 results marked a sharp turnaround from the year-ago period when Argenx lost $1.25 per share. Sales skyrocketed 73% year-over-year as well, underscoring the remarkable growth trajectory the biotech firm is on.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。